Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Emergence and spread of antimicrobial resistance (AMR)
- Introduction to antimicrobial resistance
- Mechanisms of antibiotic action and antibiotic resistance
- Why does AMR occur?
- Timeline for observed antibiotic resistance development
- AMR is a global public health threat and economic burden
- What does this mean for us?
- Levels of antibiotic resistance worldwide associated with major bacterial pathogens
- Global spread of antibiotic resistant bacteria
- AMR threat in the United States
- Global AMR threat
- Vaccines differ from antibiotics in their mechanisms of action
- Actions induced by a vaccine
- A vaccine mechanism of action differs to that of an antibiotic
- Vaccines have a direct and indirect impact on AMR
- What is herd immunity?
- Licensed vaccines have a proven ability to fight AMR
- Haemophilus influenzae type b (Hib)
- Hib polysaccharide conjugate vaccines
- Impact of the Hib polysaccharide conjugate vaccine
- Pneumococcal disease
- Pneumococcal polysaccharide conjugate vaccines (PCVs)
- PCVs reduce IPD
- PCV13 reduced the incidence of antibiotic-non-susceptible IPD
- PCV7 reduced the rates of antibiotic prescriptions
- Prevnar uptake in babies induced herd immunity in adults
- Typhoid vaccines
- S. Typhi polysaccharide conjugate vaccines
- Impact of Vi-conjugate vaccines
- Influenza virus
- Seasonal influenza vaccines
- Seasonal influenza vaccines prevent AMR
- Rotavirus is a leading cause of diarrhea in infants
- Impact of rotavirus vaccines on disease burden and spread of AMR
- Summary
Topics Covered
- An introduction to Antimicrobial Resistance (AMR)
- The emergence and spread of AMR
- The mechanism of action of vaccines
- The impact of vaccines on AMR
- Herd immunity
- Licensed vaccines and their ability to fight AMR
- H. influenzae type b polysaccharide conjugate vaccines
- Pneumococcal polysaccharide conjugate vaccines (PCVs)
- S. Typhi polysaccharide conjugate vaccines
- Seasonal influenza vaccines
- Rotavirus vaccines
Links
Series:
Categories:
Therapeutic Areas:
External Links
- CDC resource on Haemophilus influenzae disease
- CDC resources on influenza (flu)
- WHO resource on influenza (flu)
- CDC 2017 and 2018 reports on antibiotic use in the U.S.
- WHO monitoring and surveillance data of rotavirus
- CDC surveillance of rotavirus in the U.S.
- Examples of how seasonal influenza vaccines prevent AMR
Talk Citation
Anderson, A.S. (2021, July 28). Vaccines and the fight against antimicrobial resistance 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/GSZE3084.Export Citation (RIS)
Publication History
Financial Disclosures
- Annaliesa S. Anderson is an employee of Pfizer Inc. and may hold stock or stock options.
Vaccines and the fight against antimicrobial resistance 1
Published on July 28, 2021
39 min
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name's Dr. Annaliesa Anderson, and I'm the Chief Scientific Officer
for Bacterial Vaccines at Pfizer.
My disclosure is that I work for Pfizer, and as such, I'm paid by Pfizer.
Today I'm going to talk about the importance of vaccines in reducing antibiotic exposure,
and preventing antimicrobial resistance.
0:20
I'll be conducting this lecture in two parts.
The first part will introduce what antimicrobial resistance is, and discuss its emergence and spread.
I'll explain how vaccines differ from antibiotics in their mechanism of action, and I'll also give
some examples of licensed vaccines that have had a documented and proven ability
to fight antimicrobial resistance.
In the second part of this lecture, I will be giving some examples where vaccines
don't currently exist against specific pathogens of concern for antimicrobial resistance,
and the work that is being done to develop vaccines that can protect against these diseases.
I'll be giving an overview of the global mobilization actions by different agencies,
to implement the use of vaccines to prevent antimicrobial resistance.
I'll discuss barriers to maximizing licensed vaccines in the fight against AMR,
and talk about efforts that are being made towards better utilization of vaccines against AMR.
1:32
In this first section, I'll talk about the emergence and spread of antimicrobial resistance.
1:39
Antimicrobial resistance is a natural evolutionary process.
It occurs when pathogens - such as bacteria - change, and find ways to resist the effects
of the drugs that are used to treat them (in this case, antibiotics).
The pathogens can survive, grow, and spread their resistance to other bacteria, and
this process of adaptation leads to antimicrobial resistance.